Genemedicine Co., Ltd.

Industry-University Cooperation Foundation Hanyang University

Korea Research Institute of Bioscience and Biotechnology

Okayama University

Momotaro-gene Inc.

Iucf-hyu

Pharmabcine Inc.

Theragenetex Co., Ltd.

Chae Ok Yun

Young Ho Kim

Hee Gu Lee

Kyung-Sook Chung

Yu-Kyoung Oh

Young Joo Kim

Eun Young Song

Moon Hee Kim

Kyeong-Eun Jung

Jung-Sun Lee

Kyung Bin Song

Misun Won

Hye Kyung Hong

Young Woo Park

Min Young Kim

Jin Won Lee

Hiromi Kumon

Sung Woo Kim

Young Il Yeom

Semi Kim

Masami Watanabe

Do Yun Kim

Dong Heon Lee

A-Rum Yoon

Yasutomo Nasu

Weon Sup Lee

Sang Ryeol Shim

Eun Jung Baek

Kwi Hwa Kim

Jin San Yoo

Jae Won Jeon

Young Myeong Kim

Sang Seok Koh

Dayananda Kasala

Chul Geun Kim

Young Guen Kwon

Chan Gil Kim

Su Jae Lee

Dae Hyun Ha

Young Su Lim

Jeong Ki Min

Joung-Woo Choi

Bo Jeong Pyun

Won Jai Lee

Kasala Dayananda

Mi Hee Park

Hyo Min Ahn

Ho Chul Kang

Ji Hyung Chae

Joon Chul Lee

Je Min Choi

Hyun Sook Jang

Yan Li

Hyung Sik Won

Youjin Na

Seung Han Son

Eon Ju Oh

Dong Sup Lee

Geun Bae Rha

Too Hyon Cho

Jeong Eun Kang

Nahm Ju Kim

Hyeon Mi Yoo

Sam Sook Sul

Disclosed is a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction. A pH-sensitive and bioreducible polymer contains (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages. The and to a pharmaceutical composition containing the polymer-virus complex. Also disclosed are a pharmaceutical composition containing the pH-sensitive and bioreducible polymer-virus complex and methods for treating cancer in a subject, employing the composition.

PH-sensitive and bioreducible polymer-virus complex for cancer treatment

The present invention relates to: recombinant adenoviruses, which have an excellent ability to be introduced into stem cells and can be easily introduced into stem cells even at a low concentration; stem cells comprising the same; a gene delivery composition; and a pharmaceutical composition. Stem cells into which adenoviruses are introduced, of the present invention, have excellent in vivo survivability and a treatment effect on tumor cells, and, when used as an anticancer drug, do not cause problems with respect to in vivo survival, hepatotoxicity and the like of stem cells so as to be particularly usable for systemic administration, and have an excellent anticancer effect even in small doses, thereby being widely usable as an anticancer drug using adenoviruses.

Recombinant adenoviruses and stem cells comprising same

The present invention relates to an anticancer composition comprising a tumor-specific oncolytic adenovirus and an immune checkpoint inhibitor. The recombinant adenovirus having IL-12 and shVEGF, or IL-12 and GM-CSF-RLX inserted therein, according to the present invention, exhibits an excellent anticancer effect by enhancing immune functions, and such anticancer effect has been confirmed to be notably enhanced through concomitant administration with an immune checkpoint inhibitor, and thus the present invention may be used as a key technique in the field of cancer treatment.

Anticancer composition comprising tumor-specific oncolytic adenovirus and immune checkpoint inhibitor

The present invention relates to an adenovirus complex which can be utilized for gene delivery and gene therapy by targeting neurotensin receptors. The complex of the present invention has an excellent antitumor effect because of a high intracellular gene transfer efficiency and target specificity by neurotensin receptor-specific binding, has little hepatotoxicity and immunogenicity, forms a stable complex, has low immunogenicity, and thus has a low loss in blood even in an in vivo environment. Therefore, the complex of the present invention can be effectively used for gene therapy.

Adenovirus complex for gene delivery and gene iherapy

The present invention relates to a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction, to a pH-sensitive and bioreducible polymer, and to a pharmaceutical composition containing the polymer-virus complex.

Ph-sensitive and bioreducible polymer-virus complex for cancer treatment

The present disclosure relates to a composition for transduction of a virus in a cell by using a crosslinked product of PEGylated magnetic nanoparticles and catechol grafted poly-L-lysine by application of an external magnetic field. When the composition is used, a virus may be delivered into cells more rapidly and efficiently than in intracellular uptake of a virus by CAR-mediated endocytosis.

Virus-PCION complex having enhanced antitumor effect by using electromagnetic field

The present invention relates to a pharmaceutical composition for preventing or treating a keloid disease or scars. The inventors of the present invention discovered that mortalin expression inhibition and the interaction between mortalin and p53 may be new targets for keloid treatment. In the present invention, apoptosis and an anti-fibrotic effect were verified by preparing a mortalin-specific shRNA (dE1-RGD/GFP/shMOT) and injecting same in a keloid spheroid. Thus, by reducing ECM expression and inducing apoptosis in a keloid spheroid, mortalin knockdown may be very usefully employed for keloid treatment.

Composition for preventing or treating keloid or hypertrophic scars

The present invention relates to a complex of an antitumor adenovirus coated with ErbB-PEG-PAMAM and the use thereof. When using the complex of the present invention, a tumor cell-specific gene transfer effect by an excellent tumor cell infiltration ability is excellent, hepatotoxicity is low, a blood flow retention time is prolonged. Thus, the complex of the present invention can be used as a pharmaceutical composition for the treatment of a tumor and a gene therapy agent which can be administered systemically.

Complex of adenovirus and PAMAM-PEG-Erbitux, and use thereof

The present invention relates to a composition for intracellular delivery containing an adenovirus protein VI-derived peptide and an anti-cancer pharmaceutical composition containing the same. According to the present invention, the use of the peptide or peptide-polymer composite of the present invention improves intracellular delivery efficiency of a nucleic acid, a peptide, a poly-peptide, an antibody, a chemical material, or a virus. Therefore, the peptide or peptide-polymer composite of the present invention can be favorably used as an intracellular delivery system for various therapeutics.

Composition for intracellular delivery containing adenovirus protein VI-derived peptide and anticancer pharmaceutical composition containing same

A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.

Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient

An object of the present invention is to provide a conditionally replicating adenovirus having a strong anticancer effect. A conditionally replicating adenovirus to replicate specifically in a cancer cell and express REIC protein or REIC C domain protein, wherein the conditionally replicating adenovirus is obtained by inserting full-length REIC DNA or REIC C domain DNA into a conditionally replicating adenovirus comprising an ITR (inverted terminal repeat) sequence of an adenovirus type 5 genome and insertion of an HRE sequence, an hTERT promoter, a decorin-encoding DNA, and a DNA encoding a peptide comprising an RGD sequence.

Conditionally replicating adenovirus to express REIC gene

The present invention relates to a complex of PPSA or PSPA polymer and a virus, and a pharmaceutical composition including the same. According to the present invention, when a polymer-virus complex formed using PPSA or PSPA polymer is used, transduction efficiency thereof to cells may be enhanced, an excellent therapeutic effect may thus be obtained when used as a pharmaceutical composition, and, therefore, the pharmaceutical agent may be useful as a therapeutic agent.

PPSA and Pspa polymer-virus complex and pharmaceutical compositions comprising the same

The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.

Anti-cancer compositions containing Wnt decoy receptor

The present invention relates to a gene expression regulating sequence consisting of a combination of HRE, E2F and TERT, and to a gene delivery system having significantly improved selective tumor cell cytotoxicity using same, and more particularly, to a recombinant adenovirus. In addition, the present invention relates to a pharmaceutical antitumor composition comprising the recombinant adenovirus. The replication of the recombinant adenovirus of the present invention is tumor-specifically regulated by the novel gene expression regulating sequence of the present invention, thus enabling the recombinant adenovirus of the present invention to exhibit improved selective tumor cell cytotoxicity or apoptotic potential, and exhibit remarkably improved antitumor effects particularly in hypoxic conditions. In addition, the specific expression of the recombinant adenovirus in tumor cells may increase in vivo stability, and thus may induce greatly improved antitumor effects.

Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence

Growing community of inventors

Seoul, South Korea

Chae Ok Yun